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Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry. At 3 years post allograft, leukemia free survival (LFS) was , overall survival (OS) 39.5% , relapse incidence (RI) , and nonrelapse mortality (NRM) . RI was higher in patients transplanted in relapse in comparison to those transplanted in CR2 (HR 1.76, P = .004) and in patients who relapsed later after ASCT (HR 0.97 per month, P < 10 −3 ), both translating into better LFS/ OS. Relapse was also lower in patients undergoing allogeneic stem cell transplantation (allo-HSCT) from an unrelated donor (UD) in comparison to those transplanted from a matched sibling donor (MSD) (HR 0.49, with better LFS/OS in patients who relapsed later post ASCT, those transplanted in CR2 and those who had not received TBI pre-ASCT.
| INTRODUCTION
During the past decades, autologous stem cell transplantation (ASCT) has been widely used as consolidation therapy in patients with acute myeloid leukemia (AML) in first or second complete remission (CR). 1, 2 However, over time, allogeneic stem cell transplantation (allo-HSCT) has become feasible for almost all patients thanks to the availability of alternative donors and the use of reduced intensity conditioning (RIC).
Thus, ASCT has become less popular.
Yet allo-HSCT is associated with higher rates of nonrelapse mortality (NRM), graft-vs-host disease (GVHD), and infection. Moreover, patients who undergo allo-HSCT tend to have a poorer quality of life compared with patients who undergo ASCT. The major impediment of ASCT in AML, however, is the high rate of relapses which has historically been reported in the first 2 years around 40%-50% in CR1 and 70% in CR2. Even in patients in CR 2 years after ASCT, relapse incidences (RI) at 5 and 10 years still have reached 11% and 16%. 8 Patients with AML who relapse after ASCT have a poor outcome but importantly, some can be rescued with an allo-HSCT.
In the past, several single institution studies with limited numbers of patients have focused on this issue. [9] [10] [11] Two historical retrospective analyses from the EBMT evaluated the outcome of patients with acute leukemias autografted in CR who relapsed and then were either treated with conventional chemotherapy and/or received a second autograft or were allografted. 12, 13 In these old studies of patients transplanted before the year 2000, the outcome at 2 years was not significantly different after a second autograft or a matched allogeneic transplant with an OS of 42 AE 6% and 32 AE 5%, respectively. Favorable prognostic factors were patient age below 25 years, an interval from the first autograft to the second transplant greater than 8 months and the absence of prior total body irradiation (TBI). Patients treated with conventional chemotherapy fared significantly worse with a 2-year-OS of 11 AE 1% only.
A more recent study in 2013 by the CIBMTR analyzed 302 patients who underwent an allo-HSCT for relapse post ASCT using grafts from UDs with either myeloablative (MAC) or RIC. 14 Allo-
HSCT with an UD after relapse post ASCT resulted in 20% leukemia free survival (LFS) at 5 years, and the best results were seen in patients with a longer interval to secondary transplantation, a Karnofsky Performance Status Score ≥ 90%, in CR at time of allotransplant, and conditioned with a RIC regimen.
Transplantation modalities have recently improved with an increase of the age limit of patients undergoing allo-HSCT, an increase in the use of UD and mismatched transplantations, and a decrease in second ASCT.
We therefore decided to analyze the registry of the ALWP of the EBMT to evaluate the outcome and determine the prognostic factors in a large series of AML patients autografted more recently, after the year 2000, who relapsed and were rescued by allo-HSCT.
| PATIENTS AND METHODS
The design of this multicenter analysis was retrospective. Adult patients In total, 537 patients matching the inclusion criteria were identified.
The list of centers contributing patient data can be found in the appendix.
| DEFINITIONS
MAC was defined as a regimen containing either TBI with a dose greater than 6 Gy, a total dose of oral BU greater than 8 mg/kg, or a total dose of intravenous BU greater than 6.4 mg/kg or Melphalan at doses >140 mg/m 2 . In addition, regimens containing two alkylating agents were considered as MAC. All other regimens were defined as RIC. 15 Cytogenetic abnormalities were classified according to MRC criteria. 16 
| ENDPOINTS
OS was defined as time from allo-HSCT to death from any cause. LFS was defined as time from allo-HSCT to relapse or progression or death from any cause. aGVHD was graded according to the modified Seattle-Glucksberg criteria 17 and cGVHD according to the revised Seattle criteria. 18 GvHD-free, relapse free survival (GFRFS) was defined using the EBMT definition for registry based analyses where the time to first event among the following is recorded: severe grade III or IV acute GvHD, severe GvHD, relapse, death. 19 NRM was defined as death without evidence of relapse or progression. CR was understood as complete hematologic remission and this was defined as less than 5% bone marrow blasts. Relapse was defined as presence of 5% or more bone marrow blasts after remission was obtained.
| STATISTICAL METHODS
Probabilities of OS, LFS, and GRFS were calculated using the KaplanMeier method. 20 Cumulative incidence was used to estimate the endpoints of NRM, RI, acute and chronic GVHD to accommodate for competing risks. 21, 22 To study acute and chronic GVHD, we considered relapse and death to be competing events. Univariate analyses were done using the Gray's test for cumulative incidence functions and the log rank test for OS, GRFS, and LFS. proportional hazards model. 23 In order to test for a center effect, we introduced a random effect of frailty for each center into the model. 24, 25 Probabilities of the respective survival times are reported at 3 years after allo-HSCT. Results were expressed as the hazard ratio (HR) with the 95% confidence interval (95%CI). All tests were two-sided. The type I error rate was fixed at 0.05 for the determination of factors associated Time from ASCT to relapse, months (range) (IQR)
10 (1-176) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) Time from relapse to Allo-HSCT, days (range) (IQR)
(11-385) (87-175)
Time from ASCT to Allo-HSCT, days (range) (IQR) Graft failure 31 (6) aGVHD, n (%)
Grade I 84 (17) Grade II 67 (13) Grade III 34 (7) Grade IV 27 (5.5) Grade unknown 7 (1.5) No aGVHD 280 (56) Missing 38 (Continues) 
| LFS, OS, RI, NRM, GFRS, aGvHD, and cGvHD
At 3 years post allograft (Figure 1) , extensive in 14.5%
[ of the patients.
| Univariate analysis
Results of the univariate and multivariate analyses for the respective outcomes variables are shown in Tables 2 and 3 : prognostic factors identified in univariate for at least one of the predefined endpoints and thus entered into multivariate analysis were patient age, time between ASCT and allo-HSCT, good cytogenetic group vs other, year of allo-HSCT, TBI conditioning before ASCT, disease status at allo- 
HSCT, that is, first relapse vs CR2, stem cell source for allo transplantation, patient CMV seropositivity, and RIC vs MAC conditioning.
| Multivariate analysis
By multivariate analysis, RI was higher in patients transplanted in relapse vs CR2 (HR 1.76, P = .004). RI was lower in patients who relapsed later (>10 months, documented. 7, [30] [31] [32] The combination of IV Busulfan and high dose
Melphalan as conditioning regimen has been shown to be associated with a lower RI. 4, 5 The advantage of ASCT over allo-HSCT short term relies on a lower NRM after ASCT and on a long term basis on the absence of severe chronic GVHD. Indeed, although there is no consensus, one may consider that GRFS rather than merely LFS should be the outcome to discuss with patients when explaining the risk/ benefit ratio post allo-HSCT with alternative donors as compared to the outcome post ASCT in patients in MRD negative CR1. Unfortunately, the RI post ASCT, including late relapses, has been shown to be higher than following allo-HSCT, due to the absence of a graft-vs-leukemia effect. 8 In patients allotransplanted, several attempts at reducing the RI post-transplant have given interesting results, using tyrosine kinase inhibitors such as sorafenib, 33, 34 midostaurin, 35 however that it is a retrospective study which suffers from the usual [32.1-43.8] 29.3 [24-34.9] 32.5 [26.8-38.3] 40.8 [34.8-46.9] 22.8 [17.7-28] 36.7 [28.4-44.9] 29.4 [21.7-37.5] 33.9 [25.6-42.2] 38.1 [29.4-46.7] 23.1 [15.6-30.5] Patient serology 43.8 [37.8-49.8] 24 [18.8-29. 30.8 [24.4-37.4] 32.4 [25.9-39.1] 36.8 [29.9-43.7] 42.5 [35.3-49.6] 23.6 [17.4-29.7] Donor serology Positive 34.9 [28.2-41.6] 33.8 [27.3-40.3] 31 [24.3-37.6] 41.7 [34.6-48.8 [23.5-36.9] 34.5 [27.3-41.7] 43 [35.5-50.5] 22.4 [16.2-28.6] depletion 39.9 [33.7-46.2] 24.3 [18.8-29.9 limitations among which the heterogeneity of the patient population and the various allotransplant modalities used at multiple centers stand out. It nonetheless represents the only data set available and the only possible analysis which can provide some information since there is no randomized study reported comparing various therapeutic approaches including allotransplantation in patients in relapse post ASCT. Such a study is unlikely to be launched in the coming years.
This study provides information of practical utility: it first confirms previously recognized prognostic factors such as a younger patient age, favorable cytogenetics, a longer interval from ASCT to relapse and the absence of previous TBI. It also confirms that patients allografted in CR2 have a better outcome than those transplanted in relapse.
Two Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; ASCT, autologous hematopoietic stem cell transplantation; CB, cord blood; CR, complete remission; MAC, myeloablative conditioning; mths, months; MSD, matched sibling donor; RIC, reduced intensity conditioning; TBI, Total Body Irradiation; UD, unrelated donor.
